Emerging therapies in gastrointestinal cancers
作者： Jyoti Nautiyal , Arun K Rishi , Adhip PN Majumdar
关键词: Carcinogenesis 、 Immunology 、 Oncogene Proteins v-erbB 、 Cancer research 、 Growth factor receptor 、 Biology 、 Receptor 、 Signal transduction 、 Epithelium 、 ErbB Receptors 、 Receptor tyrosine kinase
摘要: Members of the receptor tyrosine kinase family, that include EGFR, ErbB-2/HER-2, ErbB-3/HER-3 and ErbB-4/HER-4, are frequently implicated in experimental models epithelial cell neoplasia as well human cancers. Therefore, interference with activation these growth factor receptors represents a promising strategy for development novel selective anticancer therapies. Indeed, number inhibitors target either EGFR or HER-2, exception few both; have been developed treatment Since most solid tumors express different ErbB and/or their ligands, identification inhibitor(s), targeting multiple family members may provide therapeutic benefit to broader patient population. Here we describe significance an cancers, summarize available therapeutics receptors. It also emphasizes need develop pan-ErbB discusses EGF-Receptor Related Protein, recently isolated negative regulator potential wide variety
cnki.com.cn参考文章(120)
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
B Liu, M Fang, Y Lu, Y Lu, G B Mills, Z Fan, Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. British Journal of Cancer. ,vol. 85, pp. 303- 311 ,(2001) , 10.1054/BJOC.2001.1910
Deng Dh, Wen D, Liu N, Finley Gg, Salup R, Melhem Mf, Lyne Jc, Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. The cancer journal from Scientific American. ,vol. 3, pp. 21- 30 ,(1997)
E. Peles, R.B. Levy, E. Or, A. Ullrich, Y. Yarden, Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. The EMBO Journal. ,vol. 10, pp. 2077- 2086 ,(1991) , 10.1002/J.1460-2075.1991.TB07739.X
Joan Albanell, Jordi Codony, Ana Rovira, Begoña Mellado, Pere Gascón, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4 Advances in Experimental Medicine and Biology. ,vol. 532, pp. 253- 268 ,(2003) , 10.1007/978-1-4615-0081-0_21
Adhip P.N. Majumdar, Jianhua Du, James S. Hatfield, Edi Levi, Volkan Adsay, Eva M. Schmelz, Kiran K. Nagothu, Richard Jaszewski, Omer Kucuk, Fazlul H. Sarkar, Expression of EGF-receptor related protein (ERRP) decreases in gastric mucosa during aging and carcinogenesis. Digestive Diseases and Sciences. ,vol. 48, pp. 856- 864 ,(2003) , 10.1023/A:1023078924686
Y. Yarden, C. R. Zelnick, Dot Chin, D. F. Stern, S. S. Bacus, Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. American Journal of Pathology. ,vol. 148, pp. 549- 558 ,(1996)
S.A. Prigent, W.J. Gullick, Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. The EMBO Journal. ,vol. 13, pp. 2831- 2841 ,(1994) , 10.1002/J.1460-2075.1994.TB06577.X
Leslie R. Pustilnik, Kathleen Provoncha, Kenneth K. Iwata, Erling Emerson, James D. Moyer, John C. Kath, E. Gabriella Barbacci, Jitesh P. Jani, Brian P. Boscoe, Eric D. Cox, Zhengyu Liu, Penny E. Miller, Ann Marie K. Rossi, The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells Cancer Research. ,vol. 63, pp. 4450- 4459 ,(2003)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)